{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:08:56Z","timestamp":1773155336755,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ygyno.2015.02.020","type":"journal-article","created":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T08:08:54Z","timestamp":1425110934000},"page":"503-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)"],"prefix":"10.1016","volume":"137","author":[{"given":"C.L.","family":"Kushnir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Angarita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Spahlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.","family":"Sinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.J.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.L.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.L.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.02.020_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11936-014-0315-4","article-title":"Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment","volume":"16","author":"Raj","year":"2014","journal-title":"Curr. Treat. Options cardiol. Med."},{"key":"10.1016\/j.ygyno.2015.02.020_bb0010","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/annonc\/mdl484","article-title":"Pegylated liposomal doxorubicin HCL (PLD; Caelyx\/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer","volume":"18","author":"Andrepopoulou","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.02.020_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2004.09.046","article-title":"Role of pegylated liposomal doxorubicin in ovarian cancer","volume":"96","author":"Thigpen","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.02.020_bb0020","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.2002.08.171","article-title":"Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study","volume":"20","author":"Muggia","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.02.020_bb0025","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/1097-0142(20011101)92:9<2327::AID-CNCR1579>3.0.CO;2-6","article-title":"Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix","volume":"92","author":"Verschraegen","year":"2001","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2015.02.020_bb0030","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL(CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.02.020_bb0035","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative dose of 500mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann. Oncol."},{"issue":"Suppl. 4","key":"10.1016\/j.ygyno.2015.02.020_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-199700544-00005","article-title":"Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours","volume":"54","author":"Gabizon","year":"1997","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ygyno.2015.02.020_bb0045","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug Saf."},{"issue":"10","key":"10.1016\/j.ygyno.2015.02.020_bb0050","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.20207","article-title":"Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?","volume":"100","author":"Theodoulou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.02.020_bb0055","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2015.02.020_bb0060","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Sm","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.02.020_bb0070","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/CAD.0b013e32833dc3c4","article-title":"Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?","volume":"21","author":"Grenader","year":"2010","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2015.02.020_bb0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000312644","article-title":"High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies","volume":"56","author":"Kesterson","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ygyno.2015.02.020_bb0080","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2004.03.024","article-title":"Cardiac safety profile of prolonged (>6cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies","volume":"94","author":"Uyar","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.02.020_bb0085","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ygyno.2013.03.012","article-title":"Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?","volume":"129","author":"Gill","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.02.020_bb0100","author":"Nix"},{"key":"10.1016\/j.ygyno.2015.02.020_bb0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0002-9343(87)90212-9","article-title":"Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography","volume":"82","author":"Schwartz","year":"1987","journal-title":"Am. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815006629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815006629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T19:51:23Z","timestamp":1537818683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815006629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0090825815006629"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.02.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}